Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Burckart

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
Clinical Pharmacy|November 1, 1983
Monitoring cyclosporine therapyG J Burckart
Journal of Clinical Pharmacology|October 12, 1999
P-glycoprotein and drug therapy in organ transplantationA Lo, G J Burckart
American Journal of Hospital Pharmacy|June 1, 1979
Drug therapy for Reye's syndromeK D Mutchie, G J Burckart
The Journal of Pediatrics|December 1, 1981
Effect of prostaglandin E1 on the reserve bilirubin-binding capacity of albuminG J Burckart, P F Whitington
Pediatric Cardiology|January 1, 1986
Quinidine dosage in children using population estimatesG J Burckart, J Marin-Garcia
Journal of Clinical Pharmacology|November 24, 1998
Nuclear factor kappa B: important transcription factor and therapeutic targetJ I Lee, G J Burckart
Clinical Pharmacology and Therapeutics|February 18, 2010
Pediatric dose selectionD R Abernethy, G J Burckart
Journal of Medicinal Chemistry|January 1, 1978
Potential inhibitors of L-asparagine biosynthesis. 4. Substituted sulfonamide and sulfonylhydrazide analogues of L-asparagineS Brynes, G J Burckart, M Mokotoff
Clinical Toxicology|July 1, 1981
Neutropenia following acute chlorpromazine ingestionG J Burckart, J Snidow, W Bruce
Journal of Clinical Pharmacology|May 1, 1986
Cyclosporine concentration determinations for monitoring and pharmacokinetic studiesR J Ptachcinski, G J Burckart, R Venkataramanan
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
Clinical Pharmacy|November 1, 1983
Monitoring cyclosporine therapyG J Burckart
Journal of Clinical Pharmacology|October 12, 1999
P-glycoprotein and drug therapy in organ transplantationA Lo, G J Burckart
American Journal of Hospital Pharmacy|June 1, 1979
Drug therapy for Reye's syndromeK D Mutchie, G J Burckart
The Journal of Pediatrics|December 1, 1981
Effect of prostaglandin E1 on the reserve bilirubin-binding capacity of albuminG J Burckart, P F Whitington
Pediatric Cardiology|January 1, 1986
Quinidine dosage in children using population estimatesG J Burckart, J Marin-Garcia
Journal of Clinical Pharmacology|November 24, 1998
Nuclear factor kappa B: important transcription factor and therapeutic targetJ I Lee, G J Burckart
Clinical Pharmacology and Therapeutics|February 18, 2010
Pediatric dose selectionD R Abernethy, G J Burckart
Journal of Medicinal Chemistry|January 1, 1978
Potential inhibitors of L-asparagine biosynthesis. 4. Substituted sulfonamide and sulfonylhydrazide analogues of L-asparagineS Brynes, G J Burckart, M Mokotoff
Clinical Toxicology|July 1, 1981
Neutropenia following acute chlorpromazine ingestionG J Burckart, J Snidow, W Bruce
Journal of Clinical Pharmacology|May 1, 1986
Cyclosporine concentration determinations for monitoring and pharmacokinetic studiesR J Ptachcinski, G J Burckart, R Venkataramanan
Pageof 13